Open access
Open access
Powered by Google Translator Translator

Radiation Oncology

RCT | Hyaluronic acid spacer for hypofractionated prostate radiation therapy

13 Feb, 2023 | 12:25h | UTC

Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial – JAMA Oncology

 

Commentary on Twitter

 

RCT | Effects of the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer

9 Feb, 2023 | 13:45h | UTC

Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial – BJS Open

 

Commentary on Twitter

 

RCT | Medial retropharyngeal nodal region sparing radiotherapy vs. standard radiotherapy in patients with nasopharyngeal carcinoma

7 Feb, 2023 | 14:09h | UTC

Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial – The BMJ

 

SR | Partial breast irradiation for breast cancer

3 Feb, 2023 | 14:06h | UTC

Partial Breast Irradiation for Breast Cancer – Agency for Healthcare Research and Quality

 

Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years

26 Jan, 2023 | 12:04h | UTC

Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right? – Journal of Clinical Oncology

 

Commentary from the author on Twitter

 

RCT | Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer

20 Jan, 2023 | 14:19h | UTC

Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial – BJS Open

 

Commentary on Twitter

 

SR | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation

19 Jan, 2023 | 14:09h | UTC

Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation – Cochrane Library

Summary: Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation – Cochrane Library

 

RCT | MRI–guided vs. CT–guided stereotactic body radiotherapy for prostate cancer

15 Jan, 2023 | 20:05h | UTC

Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial – JAMA Oncology

News Release: MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer – University of California

 

Commentary from the author on Twitter (thread – click for more)

 

RCT | Cosmetic results and side effects of accelerated partial-breast irradiation vs. whole-breast irradiation for low-risk invasive carcinoma of the breast

15 Jan, 2023 | 19:53h | UTC

Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter

 

RCT | High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer

15 Jan, 2023 | 19:51h | UTC

High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538 – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

NCCN Guideline | Pediatric central nervous system cancers

12 Jan, 2023 | 13:11h | UTC

Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Editorial: ASCO Living Guidelines: The Next Frontier

 

Cohort Study | 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

11 Jan, 2023 | 14:10h | UTC

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter (thread – click for more)

 

RCT | Neoadjuvant chemotherapy with CAPOX vs. chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia

10 Jan, 2023 | 14:09h | UTC

Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial – Annals of Surgery

 

Post-trial follow-up | Radiotherapy vs. surgery of the axilla after a positive sentinel node in breast cancer.

14 Dec, 2022 | 14:42h | UTC

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: ART Preferred Over ALND in Sentinel Node-Positive Early Breast Cancer – Cancer Therapy Advisor

 

RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.

12 Dec, 2022 | 12:40h | UTC

Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Quick Guide for Radiation Oncologists | Everything you always wanted to know about sarcopenia but were afraid to ask.

21 Nov, 2022 | 14:29h | UTC

Everything You Always Wanted to Know about Sarcopenia but Were Afraid to Ask: A Quick Guide for Radiation Oncologists (impAct oF saRcopeniA In raDiotherapy: The AFRAID Project) – Current Oncology 

 

RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.

11 Nov, 2022 | 13:55h | UTC

[News release – not published yet] Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – American Society for Radiation Oncology (ASTRO) Annual Meeting

 

Single-arm P2 study | Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas.

9 Nov, 2022 | 12:24h | UTC

Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Shorter course of radiation therapy yields comparable results for patients with non-metastatic soft tissue sarcoma – The University of Texas MD Anderson Cancer Center

 

Phase 2 RCT | Concurrent Bevacizumab and reirradiation vs. Bevacizumab alone as treatment for recurrent glioblastoma.

9 Nov, 2022 | 12:21h | UTC

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Bevacizumab Plus Reirradiation Improves PFS in Glioblastoma Multiforme – OncLive

 

SR | Efficacy and safety of stereotactic body radiotherapy for painful bone metastases.

8 Nov, 2022 | 12:00h | UTC

Efficacy and safety of stereotactic body radiotherapy for painful bone metastases: Evidence from randomized controlled trials – Frontiers in Oncology

 

Post-trial follow-up | Long-term outcomes with stereotactic radiosurgery vs. whole-brain RT for resected brain metastasis.

7 Nov, 2022 | 12:22h | UTC

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Survivors face less late cognitive deterioration after stereotactic radiosurgery than WBRT – medwire News

Original Study: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Cohort Study | Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer.

3 Nov, 2022 | 13:39h | UTC

Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)

Commentaries:

Sinoatrial Node Radiation During CRT May Increase Risk of Atrial Fibrillation in SCLC and NSCLC – Cancer Network

Incidental sinoatrial node irradiation may increase AF risk in lung cancer – medwire News

 

Commentary on Twitter

 

[News Release] RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.

27 Oct, 2022 | 12:32h | UTC

News Release: Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – ASTRO Annual Meeting

Abstract: Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 7-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial – ASTRO Annual Meeting

 

Single-arm P2 study | Toxic effects of stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer.

26 Oct, 2022 | 14:28h | UTC

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Stereotactic Ablative Body Radiotherapy Produces Acceptable Toxic Effects in Patients With Cancer and Oligometastses – Cancer Network

 

Commentary on Twitter

 

Phase 2 RCT | Nivolumab with or without Ipilimumab combined with stereotactic body radiotherapy for metastatic pancreatic cancer.

24 Oct, 2022 | 14:01h | UTC

Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: SBRT Plus Nivolumab/Ipilimumab Yields Meaningful Activity in Metastatic Pancreatic Cancer – Cancer Network

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.